Clinical Trials & Research Studies in United Kingdom(Updated 8/25)

Atrial Functional Mitral Regurgitation and Tricuspid Regurgitation

NCT05920824

Recruiting

A prospective, observational cohort study designed to identify clinical phenotypes and evaluate predictors \& outcomes of functional mitral and tricuspid valve regurgitation in patients with atrial fibrillation. Participant will under go: * Baseline echocardiography * Cpex Echocardiography * Blood test: BNP * 1 year follow up Echocardiography Participants will be stratified into three subgroups: * Atrial Functional MR * Atrial Functional TR * Mixed MR \& TR

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: St Bartholomew's Hospital, London, Not set

Conditions: Atrial Fibrillation, Functional Mitral Regurgitation, Functional Tricuspid Regurgitation

Register for Updates

Learn More ›

A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions

NCT06864195

Recruiting

Liver cancer is often diagnosed too late for effective treatment. The VOCAL2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis. The test analyzes tiny chemicals in exhaled breath called volatile organic compounds (VOCs) to identify signs of liver disease. Who can take part? Adults aged 18 or older who: Have liver cancer (hepatocellular carcinoma or cholangiocarcinoma), or Have liver cirrhosis or primary scler... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: Imperial College London, London, Not set

Conditions: Liver Cirrhosis, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Cholangitis, Sclerosing

Register for Updates

Learn More ›

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

NCT04817618

Recruiting

The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.

Gender:

ALL

Ages:

Between 12 years and 60 years

Trial Updated:

03/01/2025

Locations: Childrens Hospital Colorado, Aurora, Colorado +81 locations

Childrens Hospital Colorado, Aurora, Colorado

Nicklaus Childrens Hospital, Miami, Florida

Georgia Nephrology Research Inst, Lawrenceville, Georgia

University of Iowa Health Care, Iowa City, Iowa

Johns Hopkins Hospital, Baltimore, Maryland

Brigham and Womens Hosp Harvard Med School, Boston, Massachusetts

Albany Medical Center, Albany, New York

Col Uni Med Center New York Presby, New York, New York

Baylor Scott and White Research, Temple, Texas

Novartis Investigative Site, Caba, Buenos Aires

Novartis Investigative Site, Buenos Aires, Not set

Novartis Investigative Site, Cordoba, Not set

Novartis Investigative Site, Edegem, Not set

Novartis Investigative Site, Leuven, Not set

Novartis Investigative Site, Belo Horizonte, MG

Novartis Investigative Site, Pernambuco, Recife

Novartis Investigative Site, Passo Fundo, RS

Novartis Investigative Site, Joinville, Santa Catarina

Novartis Investigative Site, Santo Andre, SP

Novartis Investigative Site, Sao Paulo, SP

Novartis Investigative Site, Salvador, Not set

Novartis Investigative Site, London, Ontario

Novartis Investigative Site, Toronto, Ontario

Novartis Investigative Site, Montreal, Quebec

Novartis Investigative Site, Guangzhou, Guangdong

Novartis Investigative Site, Beijing, Not set

Novartis Investigative Site, Shanghai, Not set

Novartis Investigative Site, Wuhan, Not set

Novartis Investigative Site, Praha, Not set

Novartis Investigative Site, Lille, Not set

Novartis Investigative Site, Marseille, Not set

Novartis Investigative Site, Montpellier 5, Not set

Novartis Investigative Site, Paris 15, Not set

Novartis Investigative Site, Paris, Not set

Novartis Investigative Site, Aachen, Not set

Novartis Investigative Site, Erlangen, Not set

Novartis Investigative Site, Essen, Not set

Novartis Investigative Site, Hamburg, Not set

Novartis Investigative Site, Hannover, Not set

Novartis Investigative Site, Heidelberg, Not set

Novartis Investigative Site, Mainz, Not set

Novartis Investigative Site, Athens, Not set

Novartis Investigative Site, Heraklion Crete, Not set

Novartis Investigative Site, Thessaloniki, Not set

Novartis Investigative Site, New Delhi, Delhi

Novartis Investigative Site, Hyderabad, Telangana

Novartis Investigative Site, Lucknow, Uttar Pradesh

Novartis Investigative Site, Dehradun, Uttarakhand

Novartis Investigative Site, New Delhi, Not set

Novartis Investigative Site, Petach Tikva, Not set

Novartis Investigative Site, Ranica, BG

Novartis Investigative Site, Milano, MI

Novartis Investigative Site, Roma, RM

Novartis Investigative Site, Nagoya, Aichi

Novartis Investigative Site, Asahikawa, Hokkaido

Novartis Investigative Site, Sapporo, Hokkaido

Novartis Investigative Site, Takatsuki, Osaka

Novartis Investigative Site, Ohtsu, Shiga

Novartis Investigative Site, Niigata, Not set

Novartis Investigative Site, Leiden, Zuid Holland

Novartis Investigative Site, Nijmegen, Not set

Novartis Investigative Site, Malaga, Andalucia

Novartis Investigative Site, Sevilla, Andalucia

Novartis Investigative Site, Barcelona, Catalunya

Novartis Investigative Site, Puerto De Sagunto, Comunidad Valenciana

Novartis Investigative Site, Madrid, Not set

Novartis Investigative Site, Bern, Not set

Novartis Investigative Site, Lausanne, Not set

Novartis Investigative Site, Istanbul, TUR

Novartis Investigative Site, Ankara, Not set

Novartis Investigative Site, Istanbul, Not set

Novartis Investigative Site, Talas Kayseri, Not set

Novartis Investigative Site, Glasgow, Not set

Novartis Investigative Site, London, Not set

Novartis Investigative Site, Newcastle upon Tyne, Not set

Conditions: C3G

Register for Updates

Learn More ›

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

NCT02715284

Recruiting

This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/28/2025

Locations: GSK Investigational Site, Birmingham, Alabama +129 locations

GSK Investigational Site, Birmingham, Alabama

GSK Investigational Site, Goodyear, Arizona

GSK Investigational Site, Scottsdale, Arizona

GSK Investigational Site, Fayetteville, Arkansas

GSK Investigational Site, Encinitas, California

GSK Investigational Site, La Jolla, California

GSK Investigational Site, Los Angeles, California

GSK Investigational Site, Newport Beach, California

GSK Investigational Site, San Francisco, California

GSK Investigational Site, San Marcos, California

GSK Investigational Site, Santa Monica, California

GSK Investigational Site, Washington, District of Columbia

GSK Investigational Site, Miami, Florida

GSK Investigational Site, Tampa, Florida

GSK Investigational Site, Augusta, Georgia

GSK Investigational Site, Chicago, Illinois

GSK Investigational Site, Fairway, Kansas

GSK Investigational Site, Scarborough, Maine

GSK Investigational Site, Baltimore, Maryland

GSK Investigational Site, Boston, Massachusetts

GSK Investigational Site, Detroit, Michigan

GSK Investigational Site, Kansas City, Missouri

GSK Investigational Site, Farmington, New Mexico

GSK Investigational Site, Albany, New York

GSK Investigational Site, Brooklyn, New York

GSK Investigational Site, Jamaica, New York

GSK Investigational Site, New York, New York

GSK Investigational Site, Charlotte, North Carolina

GSK Investigational Site, Cleveland, Ohio

GSK Investigational Site, Columbus, Ohio

GSK Investigational Site, Hilliard, Ohio

GSK Investigational Site, Oklahoma City, Oklahoma

GSK Investigational Site, Philadelphia, Pennsylvania

GSK Investigational Site, Providence, Rhode Island

GSK Investigational Site, Dallas, Texas

GSK Investigational Site, San Antonio, Texas

GSK Investigational Site, Salt Lake City, Utah

GSK Investigational Site, Charlottesville, Virginia

GSK Investigational Site, Seattle, Washington

GSK Investigational Site, Spokane, Washington

GSK Investigational Site, Milwaukee, Wisconsin

GSK Investigational Site, Ciudad Autonoma de Buenos Aire, Not set

GSK Investigational Site, Cordoba, Not set

GSK Investigational Site, Barretos, Not set

GSK Investigational Site, Porto Alegre, Not set

GSK Investigational Site, Ribeirao Preto, Not set

GSK Investigational Site, Rio de Janeiro, Not set

GSK Investigational Site, Sao Jose Do Rio Preto, Not set

GSK Investigational Site, Sao Paulo, Not set

GSK Investigational Site, SAo Paulo, Not set

GSK Investigational Site, Calgary, Alberta

GSK Investigational Site, Edmonton, Alberta

GSK Investigational Site, Kelowna, British Columbia

GSK Investigational Site, Vancouver, British Columbia

GSK Investigational Site, Hamilton, Ontario

GSK Investigational Site, London, Ontario

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Montreal, Quebec

GSK Investigational Site, Horovice, Not set

GSK Investigational Site, Zlin, Not set

GSK Investigational Site, Copenhagen, Not set

GSK Investigational Site, Odense C, Not set

GSK Investigational Site, Bordeaux, Not set

GSK Investigational Site, Caen Cedex 5, Not set

GSK Investigational Site, Lille, Not set

GSK Investigational Site, Marseille, Not set

GSK Investigational Site, Paris, Not set

GSK Investigational Site, Saint-Herblain cedex, Not set

GSK Investigational Site, Villejuif Cedex, Not set

GSK Investigational Site, Milano, Not set

GSK Investigational Site, Modena, Not set

GSK Investigational Site, Naples, Not set

GSK Investigational Site, Roma, Not set

GSK Investigational Site, Verona, Not set

GSK Investigational Site, Gwangju, Not set

GSK Investigational Site, Seongnam-si Gyeonggi-do, Not set

GSK Investigational Site, Seongnam-si, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, Monterrey, Not set

GSK Investigational Site, Gdynia, Not set

GSK Investigational Site, Lublin, Not set

GSK Investigational Site, Olsztyn, Not set

GSK Investigational Site, Torun, Not set

GSK Investigational Site, Warszawa, Not set

GSK Investigational Site, Barcelona, Not set

GSK Investigational Site, Girona, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, Malaga, Not set

GSK Investigational Site, Murcia, Not set

GSK Investigational Site, Pamplona, Not set

GSK Investigational Site, Santander, Not set

GSK Investigational Site, Santiago de Compostela, Not set

GSK Investigational Site, Sevilla, Not set

GSK Investigational Site, Valencia, Not set

GSK Investigational Site, Zaragoza, Not set

GSK Investigational Site, Aberdeen, Not set

GSK Investigational Site, London, Not set

GSK Investigational Site, Manchester, Not set

GSK Investigational Site, Newcastle Upon Tyne, Not set

GSK Investigational Site, Oxford, Not set

GSK Investigational Site, Sutton, Not set

Conditions: Neoplasms

Register for Updates

Learn More ›

Treatment of Vision Disturbances Due to Corneal Irregularities by Trans-epithelial Optical Phototherapeutic Keratectomy (TE-oPTK)

NCT03841253

Recruiting

This study sets out to evaluate the EpiMaster application software for use in predicting the refractive change induced by a trans-epithelial phototherapeutic keratectomy (TE-PTK) procedure in eyes with irregularly irregular astigmatism. If validation criteria are met during the observational phase, the software refractive prediction will be used to plan the refractive correction in TE-PTK treatments.

Gender:

ALL

Ages:

Between 21 years and 70 years

Trial Updated:

02/28/2025

Locations: London Vision Clinic, London, Not set

Conditions: Corneal Astigmatism

Register for Updates

Learn More ›

Use of Indocyanine Green During Primary Repair of Oesophageal Atresia and Distal Tracheo-oesophageal Fistula

NCT05735964

Recruiting

This study aims to look at babies having a primary or delayed primary oesophageal repair for OA with dTOF to evaluate if using Indocyanine green (ICG) and near infrared fluorescence (NIRF) can decrease the rates of anastomotic leaks and/or predict which patients they will happen in. The latter evaluation would help counsel parents and mean that further research can evaluate if other tactics can prevent the leak being a moderate or severe problem. These may include, but not be limited to, extra a... Read More

This study aims to look at babies having a primary or delayed primary oesophageal repair for OA with dTOF to evaluate if using Indocyanine green (ICG) and near infrared fluorescence (NIRF) can decrease the rates of anastomotic leaks and/or predict which patients they will happen in. The latter evaluation would help counsel parents and mean that further research can evaluate if other tactics can prevent the leak being a moderate or severe problem. These may include, but not be limited to, extra anastomotic sutures, insertion of a chest drain at the time of surgery (if this had not previously been considered) delaying oral feeding or using medications to dry up the saliva prophylactically (these medications have been shown to reduce the length of time it takes leaks to seal). Any technique that can reduce leak rates in oesophageal atresia is to be welcomed. Additionally ICG may artifactually affect both peripheral oxygen readings (cause a transient decrease) and cerebral near infrared spectroscopy (NIRS) values (cause a transient increase). This is due to the temporary, dose dependent, interference of the dye with the mechanism of action of the monitoring rather than a physiological effect on oxygen levels. To date there has been no study investigating the effects of ICG on oxygen saturation and cerebral NIRS in neonates undergoing OA and/or dTOF repair. The theory is an extension from adult practice following oesophagectomy for cancer where there was a reduction in anastomotic leaks when using ICG/NIRF perfusion assessment. Another study in bariatric surgery using an enteral ICG/NIRF assessment was highly sensitive for anastomotic leaks allowing management of them intra-operatively. Objectives are to 1. Identify if the appearances of ICG/NIRF can predict anastomotic leaks 2. Identify if the ICG/NIRF images would engender a change in operative management leading to a reduced leak rate 3. Give a detailed report on the effects of ICG on oxygen readings This would be a cohort pilot study of 20 patients with the aim of informing a subsequent multi-centre Randomised controlled trial Read Less

Gender:

ALL

Ages:

1 year and below

Trial Updated:

02/28/2025

Locations: Birmingham children's hospital, Birmingham, Not set

Conditions: Tracheo-Esophageal Fistula With Atresia of Esophagus

Register for Updates

Learn More ›

The Next Step Towards the Elimination of Iodine Deficiency and Preventable Iodine-related Disorders in Europe

NCT06801691

Recruiting

In the EUthyroid2 intervention, measures are being developed and implemented in educational settings across the UK, Germany, Slovenia, the Republic of Cyprus, Bangladesh, and Pakistan to effectively raise awareness of the risks associated with iodine deficiency. Each participating country will employ three measurement points. The intervention will be tailored to the specific contextual characteristics of each implementation site. A process evaluation utilizing a convergent parallel mixed methods... Read More

Gender:

ALL

Ages:

Between 13 years and 17 years

Trial Updated:

02/27/2025

Locations: Bangladesh University of Health, Dhaka, Not set +5 locations

Conditions: Iodine Deficiency

Register for Updates

Learn More ›

Heart Failure in Patients With Diabetes: Cells, Crosstalk and Consequences

NCT06774014

Recruiting

This will be an observational study to explore differences in pathophysiology between groups of people with and without heart failure (HF) (reduced and preserved ejection fraction) and with and without diabetes mellitus (DM) with a particular focus on cross-talk (fat, muscle, vascular tissue and the heart). The investigators will invite 600 people to partcipate (100 with HFrEF+DM, 100 with HFpEF+DM, 100 with HFpEF-DM, 100 with HFrEF-DM, 100 with DM, 100 without either HR or DM). Special heart sc... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire

Conditions: Diabetes Mellitus Type 2, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction

Register for Updates

Learn More ›

GEKO Venous Thromboembolism Prevention Study

NCT05476913

Recruiting

This multicentre, randomised geko™ venous thromboembolism (VTE) prevention study will prospectively collect clinical data on VTE occurrences in immobile patients after stroke, who will be randomised, on a 1:1 allocation, to receive either standard of care (Intermittent Pneumatic Compression) or geko™ neuromuscular electrostimulation device. The aim is to assess the prevention of VTE during a follow-up period of 90 days (three months) post-randomisation.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: West Suffolk Hospital, Bury St Edmunds, Suffolk +17 locations

Conditions: Stroke, Acute, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism

Register for Updates

Learn More ›

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study

NCT05653193

Recruiting

This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients with chronic lung disease like Chronic Obstructive Lung Disease (COPD) or previously treated tuberculosis (TB). It causes gradual destruction of lung tissue by slowly enlarging cavities, frequent secondary infections and poor quality of life. Because of its indolent nature and nonspecific x... Read More

This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients with chronic lung disease like Chronic Obstructive Lung Disease (COPD) or previously treated tuberculosis (TB). It causes gradual destruction of lung tissue by slowly enlarging cavities, frequent secondary infections and poor quality of life. Because of its indolent nature and nonspecific x-ray findings, it often remains unrecognised for years. Around 3600 people live with CPA in the United Kingdom. Mortality from CPA may be up to 40% in five years. Treatment for CPA relies on antifungals for prolonged periods, but only around 60% of patients improve. It is often long-term or lifelong as the response is slow and some patients experience relapses. In addition, only one class of oral antifungal drugs is licensed for CPA, and they are associated with side effects and high cost. Better treatments are needed for CPA. We do not know why many patients do not respond to treatment. Maybe CPA patients have a weakened immune system and are more susceptible to Aspergillus. Our data suggest that CPA patients produce lower amounts of ΙFNγ, a substance that facilitates the immune system's response against Aspergillus. We have also shown that, when given to patients with CPA who have failed to improve on antifungal treatment, interferon-gamma leads to improvement in important patient-centred outcomes like flares of lung disease or hospital admissions. Interferon-gamma is already in use in the National Health Service of the United Kingdom for other indications. Therefore, its use in CPA should be explored. However, CPA is a rare condition and the tolerability of interferon-gamma is not fully established in these patients. To understand whether a large-scale study is feasible in CPA, we first need preliminary data in smaller numbers of patients. We are conducting a randomised trial of interferon-gamma in addition to antifungals in CPA. Patients with CPA starting antifungal treatment are eligible. Participants (25 per group) are randomly assigned to interferon-gamma for 12 weeks (in addition to antifungals) or antifungals only. To test whether the treatment works, we will use measurements of the cavities on chest CT scan and scores on a quality-of-life questionnaire. We will assess for tolerability of treatment at intervals similar to clinical practice. Criteria for progression to the large-scale study will be set based on the proportion of patients willing to participate, and on the proportion who complete the treatment. Data collected on those parameters will allow us to determine the number needed for a definite study. If the large-scale study confirms our observations that interferon-gamma improves outcomes in CPA, then treatment duration can be shortened and relapses avoided. In addition, interferon-gamma can then be explored in other chronic lung disease. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Manchester University NHS Foundation Trust, Manchester, Not set

Conditions: Chronic Pulmonary Aspergillosis, Aspergillosis

Register for Updates

Learn More ›

Exactech Shoulder Post Market Clinical Follow-up Study

NCT05603728

Recruiting

The objective of this study is to collect and evaluate long-term clinical and radiographic outcomes data in order to better understand the safety and performance of the shoulder arthroplasty over time. This study will follow subjects long-term for a minimum of 10-years, without an early-term restriction on the amount of time they will be followed.

Gender:

ALL

Ages:

21 years and above

Trial Updated:

02/26/2025

Locations: South County Orthopedic Specialists, Laguna Woods, California +37 locations

South County Orthopedic Specialists, Laguna Woods, California

Stanford Health Care, Redwood City, California

Alpine Orthopaedic Medical Group, Stockton, California

Western Orthopaedics, Denver, Colorado

Orthopaedic and Spine Center of the Rockies, Fort Collins, Colorado

UF Health Orthopaedics and Sports Medicine Institute, Gainesville, Florida

Mayo Clinic, Jacksonville, Florida

Palm Beach Orthopaedic Institute, Palm Beach Gardens, Florida

Florida Atlantis Orthopedics, Palm Beach Gardens, Florida

Orthopaedic Medical Group of Tampa Bay, Tampa, Florida

Orthopedic and Sports Medicine, Augusta, Georgia

OrthoIllinois, Rockford, Illinois

Barrington Orthpedic Specialists, Schaumburg, Illinois

Henry Ford Health, Detroit, Michigan

Hospital for Joint Diseases - NYU Langone Health, New York, New York

Lenox Health Greenwich Village, New York, New York

Southeastern Sports Medicine and Orthopedics, Asheville, North Carolina

Duke Department of Orthopedic Surgery, Durham, North Carolina

Crystal Clinic Orthopaedic, Akron, Ohio

Charleston Orthopaedic Associates, Charleston, South Carolina

Steadman Hawkins Clinic of the Carolinas, Greenville, South Carolina

Bone and Joint Institute of Tenessee, Franklin, Tennessee

Atlantic Orthopaedics Specialists, Virginia Beach, Virginia

Orthopaedic Associates of Wisconsin, Pewaukee, Wisconsin

St Joseph's Health Care, London, Ontario

Clinique Chenieux, Limoges, Not set

Centre de l'arthrose, Mérignac, Not set

Clinique Mutualiste La Sagesse, Rennes, Not set

Policlinico Morgagni, Catania, Not set

Campolongo Hospital, Eboli, Not set

Circle Health Group, Reading, Berks

Yeovil District Hospital NHS Foundation Trust, Yeovil, Summerset

The Sulis Hospital Bath, Bath, Not set

Bedford Hospital, Bedford, Not set

Ipswich Hospital, Ipswich, Not set

Leicester General Hospital, Leicester, Not set

University Hospital South Manchester, Manchester, Not set

Nottingham University Hospital, Nottingham, Not set

Conditions: Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections

Register for Updates

Learn More ›

Evaluation of Outcomes Following Rotator Cuff Repair Using the REGENETEN Bioinductive Implant: a Prospective, Multi-Center Global Registry

NCT06857084

Recruiting

This prospective, single-arm, multicenter registry is being conducted to collect real world post-market data from patients who are undergoing rotator cuff repair using the REGENETEN◊ Bioinductive Implant System. The Registry will include up to 50 centers in the United Kingdom (UK), Europe, Australia, and up to 400 patients for the initial evaluation. Patients will be treated and evaluated according to standard medical care. Outcome data is collected up to 2 years post-surgery.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/26/2025

Locations: Melbourne Orthopaedic Group, Windsor, Victoria +18 locations

Conditions: Rotator Cuff Injuries

Register for Updates

Learn More ›

All Clinical Trials in United Kingdom

Match to Clinical Trials